A medical oncologist provides insights into the significance of CGP in their field, particularly its multi-analyte nature incorporating DNA, RNA, and supplemental protein markers. They highlight key markers such as HER2 and PD-L1 and discuss the importance of companion diagnostics for treatment decision support. The stakeholder stresses the importance of RNA coverage for detecting fusion genes and also emphasizes the importance of prognostic markers and their impact on counseling patients. The stakeholder’s role in CGP testing includes ordering tests, selecting manufacturers, and interpreting results. When selecting manufacturers, they mention several companies as key players in the CGP testing space. They also highlight pain points inCGP testing, such as high costs, challenges with RNA and protein analysis, limitations in germline and somatic DNA testing, and issues with EMR integration. In terms of changes in the future, the stakeholder expects improvements in assessing RNA and protein in as part of theCGP workflow.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.